Live Breaking News & Updates on Transgene

Stay updated with breaking news from Transgene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

New immunological data assessed by tetramer staining confirms the induction of T cell responses in treated patients All trial patients treated with TG4050 monotherapy continue to remain in remission ....

Mecklenburg Vorpommern , United Kingdom , United States , Joseph Jasper , Stefan Klotter , Institut Curie , Masamitsu Kitase , Transgene Euronext , Jean Pierre Delord , Sylvie Berrebi , Alexandra Martinez , Le Tourneau , Christophe Le Tourneau , Alessandro Riva , Lucie Larguier , Yujie Zhao , Christian Ottensmeier , American Society Of Clinical Oncology , Head Of Surgical Department , Ai Drug Development Division , Corporate Communications , Nec Ai Drug Development Business , Clatterbridge Cancer Centre , Life Science Division , University Of Liverpool , Head Of The Department Drug Development ,

BioInvent and Transgene and report positive BT-001 data

Tumour treatment among all phase 1a cohorts in were concluded with no safety concerns - News - PharmaTimes ....

Martin Welschof , Bioinvent International , T 001 ,

Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer

TG6050 is an oncolytic virus derived from Transgene's Invir.IO® platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody, with the potential to trigger a powerful antitumor immune response. ....

United States , Maud Brandely , Lucie Larguier , Sylvie Berrebi , Transgene Euronext , American Association For Cancer Research , Corporate Communications , Phasei Delivir , Euronext Paris , Chief Medical Officer , American Association , Cancer Research , Annual Meeting , Artificial Intelligence , Risk Factors , Universal Registration Document , Gefallene Big Techs ,

Transgene : Inside Information / Other news releases

P R E S S R E L E A S E

Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered. | May 10, 2023 ....

United States , Maud Brandely , Transgene Euronext , Sylvie Berrebi , Lucie Larguier , Corporate Communications , American Association For Cancer Research , Patient Dosed , Phasei Trial Evaluating , Armed Oncolytic Virus Administered Intravenously , Non Small Cell Lung Cancer , Phasei Delivir , Euronext Paris , Chief Medical Officer , American Association , Cancer Research , Annual Meeting , Artificial Intelligence , Risk Factors , Universal Registration Document , Transgene Stock Exchange , Press Release , Irus Tng Fr0005175080 ,

Study explores the role of dynamin protein DYN-1 in regenerative axonal fusion

A study explores the role of the dynamin protein DYN-1 in axonal fusion. The axon is a long, thin protrusion of nerve cells that carries electrical impulses. ....

Brent Neumann , Emily Henderson ,